NIH-funded study of people with type 1 diabetes shows safety, efficacy benefits of new system
A multicenter randomized clinical trial evaluating a new artificial pancreas system – which automatically monitors and regulates blood glucose levels – has found that the new system was more effective than existing treatments at controlling blood glucose levels in people with type 1 diabetes. The trial was primarily funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health.
The study showed that the system improved participants’ blood glucose control throughout the day and overnight. The latter is a common but serious challenge for children and adults with type 1 diabetes, since blood sugar can drop to dangerously low levels when a person is asleep. The research is published in the New England Journal of Medicine.
The artificial pancreas, also known as closed-loop control, is an “all-in-one” diabetes management system that tracks blood-sugar levels using a continuous glucose monitor (CGM) and automatically delivers the hormone insulin when needed using an insulin pump. The system replaces reliance on testing by fingerstick or CGM with separate delivery of insulin by multiple daily injections or a pump.
The International Diabetes Closed-Loop (iDCL) Study involves five separate artificial pancreas clinical protocols implemented by 10 research centers in the United States and Europe. This six-month study was the third phase in a series of trials. It was conducted with participants living their usual day-to-day lives, so the researchers could best understand how the system works in typical daily routines.
“Testing the safety and effectiveness of new technologies in real-world settings is critical to prove the usability of these systems by people with diabetes to achieve a better daily control of their blood glucose levels,” said Guillermo Arreaza-Rubín, M.D., director of NIDDK’s Diabetes Technology Program and project scientist for the study. “Earlier technologies have made the management of type 1 diabetes easier, and this research shows that this artificial pancreas system has the potential to improve health of people living with type 1 diabetes, while also potentially lifting much of the burden of care from those with the disease and their caregivers.”
This iDCL protocol enrolled 168 participants age 14 or older with type 1 diabetes. They were randomly assigned to use either the artificial pancreas system called Control-IQ or sensor-augmented pump (SAP) therapy with a CGM and insulin pump that did not automatically adjust insulin throughout the day. Participants had contact with study staff every two to four weeks to download and review device data. No remote monitoring of the systems was done, so that the study would reflect real-world use.
The researchers found that users of the artificial pancreas system significantly increased the amount of time with their blood glucose levels in the target range of 70 to 180 mg/dL by an average of 2.6 hours per day since beginning the trial, while the time in range in the SAP group remained unchanged over six months. Artificial pancreas users also showed improvements in time spent with high and low blood glucose, hemoglobin A1c, and other measurements related to diabetes control compared to the SAP group. High adherence to device use in both groups and 100% participant retention were important strengths of the study. During the study, no severe hypoglycemia events occurred in either group. Diabetic ketoacidosis occurred in one participant in the artificial pancreas group due to a problem with equipment that delivers insulin from the pump.
The Control-IQ technology was derived from a system originally developed at the University of Virginia, Charlottesville, (UVA) by a team led by Boris Kovatchev, Ph.D., director of the UVA Center for Diabetes Technology with funding support from NIDDK. In this system, the insulin pump is programmed with advanced control algorithms based on a mathematical model that uses the person’s glucose monitoring information to automatically adjust the insulin dose. Tandem Diabetes Care has submitted the results to the U.S. Food and Drug Administration for approval to market the Control-IQ system.
“This artificial pancreas system has several unique features that improve glucose control beyond what is achievable using traditional methods,” said Kovatchev. “In particular, there is a special safety module dedicated to prevention of hypoglycemia, and there is gradually intensified control overnight to achieve near-normal blood sugar levels every morning.”
Kovatchev was co-lead author of the study with colleagues Sue A. Brown, M.D., of UVA and Roy Beck, M.D., Ph.D., from the Jaeb Center for Health Research, Tampa, Florida, which was the coordinating center for the study.
“Artificial pancreas technology has tremendous potential to improve the day-to-day lives of people with type 1 diabetes,” said NIDDK Director Griffin P. Rodgers, M.D. “By making management of type 1 diabetes easier and more precise, this technology could reduce the daily burden of this disease, while also potentially reducing diabetes complications including eye, nerve and kidney diseases.”
The Latest on: Artificial pancreas
[google_news title=”” keyword=”artificial pancreas” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Artificial pancreas
- Woman Gets Diabetes, Builds Own Pancreason September 30, 2023 at 5:01 pm
Why not make the state of the insulin pump a function of the data? And thus, a sort of artificial pancreas. The project is open source for anyone to use and improve upon. She was placed on a list ...
- Fully Integrated Artificial Pancreas in Type 1 Diabeteson September 29, 2023 at 5:00 pm
These two randomized crossover studies of CLC in type 1 diabetic patients demonstrate 1) the feasibility of fully integrated subcutaneous CLC in a clinical setting, 2) the utility of modular ...
- Artificial Pancreas: What to Knowon September 21, 2023 at 5:38 am
An artificial pancreas can make a big difference in the day-to-day life of a person with type 1 diabetes. The Food and Drug Administration (FDA) has approved several versions. Type 1 diabetes is an ...
- Bio-Artificial Pancreas Market Size (New Report) Forecast Report 2023-2031on September 16, 2023 at 9:16 am
"Bio-Artificial Pancreas Market" Size, Share, Growth Report 2023-2031 | | No. of pages: 105 Report which offers an in-depth analysis Grounded on Applications (Retail, Restaurant, Hospitality ...
- Bio-Artificial Pancreas Market Demand Status 2023-2030: Insights into Business Strategies, Growth Avenues, and Upcoming Trendson September 9, 2023 at 12:16 pm
The "Bio-Artificial Pancreas Market" Research Report 2023: incorporates a thorough qualitative and quantitative analysis along with several market dynamics. Global Bio-Artificial Pancreas Market ...
- New Device May Boost Artificial Pancreas Effortson August 29, 2023 at 5:00 pm
A team of MIT engineers and collaborators may have solved a major hurdle where implantable medical devices are concerned, particularly devices designed to be used as an artificial pancreas in patients ...
- Artificial pancreas outperforms current tech in type 1 diabeteson February 5, 2023 at 6:40 am
The artificial pancreas, also known as a closed-loop control, is an “all-in-one” diabetes management system using a continuous glucose monitor (CGM) and automatically delivers insulin when ...
- Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEOon February 4, 2023 at 9:55 am
NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot study of the technology, according to chief executive Sir Simon Stevens. The diabetics ...
- ‘Artificial pancreas’ for diabetics to be rolled out on the NHSon January 27, 2023 at 9:45 am
More than 100,000 Type 1 diabetes patients will be offered an “artificial pancreas” on the NHS to help prevent amputations and blindness. People who struggle to manage their Type 1 diabetes ...
- Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Campon November 15, 2022 at 8:04 am
Recent studies have shown that an artificial-pancreas system can improve glucose control and reduce nocturnal hypoglycemia. However, it is not known whether such results can be replicated in ...
via Bing News